Inspiration Healthcare Group (IHC)

Sector:

Industrial Chemicals

Index:

FTSE AIM All-Share

 17.25p
   
  • Change Today:
      0.000p
  • 52 Week High: 53.50p
  • 52 Week Low: 15.85p
  • Currency: UK Pounds
  • Shares Issued: 89.66m
  • Volume: 6,500
  • Market Cap: £15.47m
  • RiskGrade: 227

Three AIM firms celebrate Queen's Award for Enterprise wins

By Josh White

Date: Tuesday 23 Apr 2019

LONDON (ShareCast) - (Sharecast News) - Three firms trading on London's AIM market were celebrating wins in the Queen's Award for Enterprise on Tuesday, with Inspiration Healthcare, Ergomed and Oxford BioDynamics all picking up the accolades.
Medical device company Inspiration Healthcare won the award in recognition of its "outstanding" level of International trade.

The company's board said the International Trade category recognised outstanding growth in overseas earnings and year-on-year growth in overseas sales over a six-year period.

"We are absolutely thrilled to have won the Queen's Award for Enterprise which recognises the hard work our team have put into developing our brand awareness as well as our business outside of the UK," said Inspiration Healthcare chief executive officer Neil Campbell.

"It has taken many years to establish this international presence and we are justifiably proud of the recognition through gaining the most prestigious of UK business awards.

"Looking forward, we are confident that we will continue to grow our international business by developing and launching new medical products which are specifically designed to improve patient outcomes around the world."

Specialised pharmaceutical service provider Ergomed, meanwhile, said its subsidiary PrimeVigilance was given the Queen's Award for Enterprise for the second time, this time also receiving it for International Trade.

The firm said that was in recognition of its year-on-year "outstanding" services in the drug safety sector for its global customer base.

As an International Trade winner, PrimeVigilance had demonstrated substantial growth in overseas markets and commercial success, further cementing its place as a global leader in pharmacovigilance, the board explained.

"We are delighted that Ergomed's PrimeVigilance has been honoured with a Queen's Award for the second time in recent years," said executive chairman Dr Miroslav Reljanović.

"This prestigious accolade recognises the Company's continued year-on-year international growth and reinforces Ergomed's position as a leading provider of services to the pharmaceutical industry."

Finally, Oxford BioDynamics was recognised as a winner of the 2019 Queen's Award for Enterprise, being granted it in the field of Innovation.

The company said that was demonstrative of the "outstanding" performance and commercial success of its proprietary technology platform, 'EpiSwitch', based on the latest advances in regulatory genome architecture and its functional links to patient stratifications and outcomes in oncology, neurodegenerative, inflammatory, metabolic and other indications.

"We are delighted to have been chosen for such a prestigious award, which is an outstanding achievement for the company," said Oxford BioDynamics chief executive officer Christian Hoyer Millar.

"This award is recognised worldwide as a standard of enterprise excellence, reflecting the hard work and commitment shown by our team over the years in developing real-world solutions to unmet clinical needs of high priority.

"I'd like to extend my thanks to everyone at OBD for their part in this achievement."

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

IHC Market Data

Currency UK Pounds
Share Price 17.25p
Change Today 0.000p
% Change 0.00 %
52 Week High 53.50p
52 Week Low 15.85p
Volume 6,500
Shares Issued 89.66m
Market Cap £15.47m
RiskGrade 227

IHC Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.22% above the market average65.22% above the market average65.22% above the market average65.22% above the market average65.22% above the market average
20% below the sector average20% below the sector average20% below the sector average20% below the sector average20% below the sector average
Price Trend
88.26% below the market average88.26% below the market average88.26% below the market average88.26% below the market average88.26% below the market average
46.67% below the sector average46.67% below the sector average46.67% below the sector average46.67% below the sector average46.67% below the sector average
Income
89.56% below the market average89.56% below the market average89.56% below the market average89.56% below the market average89.56% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average
Growth
94.25% below the market average94.25% below the market average94.25% below the market average94.25% below the market average94.25% below the market average
100% below the sector average100% below the sector average100% below the sector average100% below the sector average100% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 0
Sell 0
Strong Sell 0
Total 1
strong_buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

IHC Dividends

  Latest Previous
  Interim Final
Ex-Div 23-Nov-23 29-Jun-23
Paid 22-Dec-23 28-Jul-23
Amount 0.20p 0.41p

Trades for 31-Oct-2024

Time Volume / Share Price
12:02 6,500 @ 17.20p

IHC Key Personnel

COO Brook Nolson
CFO Alan Olby

Top of Page